We and others have recently reported that JNK and c‐Jun are activated in a subset of melanomas exposed to MAPK inhibitors (Delmas et al, 2015; Fallahi‐Sichani et al, 2015; Ramsdale et al, 2015; Riesenberg et al, 2015; Titz et al, 2016). The gene discussed is JUN; the disease is melanoma.